Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8773MR)

This product GTTS-WQ8773MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8773MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9841MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ2695MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ6172MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ3857MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ7642MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ7924MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ8628MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ545MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW